



FOR IMMEDIATE RELEASE

**CONTACT:** Mark Holman, CEO  
**TELEPHONE:** (530) 298-7201 ext. 707  
**EMAIL:** mark.holman@expanesthetics.com  
**WEBSITE:** www.expanesthetics.com/media  
**ADDRESS:** 1260 Lake Blvd. Ste 231, Davis, California, 95616, USA

## EXPANESTHETICS PRESENTS TO BIOTECH INDUSTRY LEADERS AT BIO 2018

By becoming a Buzz of BIO finalist, Expanesthetics earned the opportunity to present to a large crowd of biotech leaders at the 2018 BIO International Convention in June at the Boston Convention Center.



*In June, CEO Mark Holman presented to a variety of industry executives, venture funds, and healthcare leaders at BIO, the world's largest biotechnology conference.*

Attendees included venture funds, leading global pharmaceutical companies, and others with an interest in the future of anesthesia drug development from around the world. CEO Mark Holman hosted the presentation, focusing on the vision and goals of the company to bring a new generation of improved anesthetics to the market through a licensed screening technology. The presentation promoted awareness of Expanesthetics in the biotech industry and sparked conversations with multiple attendees who approached Holman following the presentation.

Expanesthetics also conducted over three-dozen meetings with collaborators and potential partners from around the world during the convention, which contributed to the convention setting a Guinness World Record for the largest business partnering event.

“One of our most exciting meetings was a meeting that was requested by the head of one of NIH’s programs for pain drug development,” Holman reported. “She had heard of us and wanted to learn more about our program. During that meeting, we learned that our current data package is now likely at the point where we will be highly competitive for non-dilutive funding starting this fall.”

Expanesthetics also launched conversations with several animal health companies from around the world regarding the company’s pain program. According to Holman, Expanesthetics hopes to form a partnership with an animal health counterpart to bring the company’s lead analgesic candidate to the animal health market, with the goal of achieving Expanesthetics’ first source of revenue. The company has continued conversations with these potential partners since the convention, digging into the science of the company’s pain program, and looks forward to solidifying a partnership in animal health.

1260 Lake Blvd Ste 231  
Davis, CA 95616  
[www.expanesthetics.com](http://www.expanesthetics.com)

This document includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Expanesthetics’ management and are subject to significant risks and uncertainties. There can be no guarantees. These statements are made as of the date of this communication and Expanesthetics assumes no obligation to provide updates.